We innovate for smarter health.

Zynnon was founded in the spirit of innovation with an ambitious objective: to offer affordable high-tech connected medical devices, together with associated services, to improve people's health and safety.

Our leadership team brings extensive experience in entrepreneurship, product development, sensor technologies and innovation in healthcare.

Our Team

Khaled Abousaleh

Chief Executive Officer

Khaled founded Zynnon in 2019 to develop a new generation of affordable medical devices to serve large numbers of people.

Prior to Zynnon, Khaled successfully started and grew his former company (Pulssar Technologies) in the liquid handling area. The company was acquired by Tecan (publicly listed company) in 2017 and Khaled joined the group as Vice President Global Sales in the Partnering Business division.

Before creating Pulssar, Khaled held several positions in engineering, project management and business development at Stago, a key player in the in vitro diagnostic market.

Khaled graduated as an engineer specialising in microtechnology from the French national school of mechanical engineering and microtechnology (ENSMM) and holds multiple patents in the area of laboratory equipment and medical devices. He speaks 5 languages.

Khaled is a two-time winner of the Bpifrance Excellence award and the Deloitte Technology Fast 50 & 500 awards.

Alex Marc

Chief Financial Officer & Investor Relations Manager

Alex has over 25 years of experience in equity capital markets. He spent the bulk of his career in sales and sales management with Morgan Stanley and Bank of America Merrill Lynch, holding senior management and head of division positions in both Switzerland and France. He was also a global relationship manager for key clients in both countries.

Most recently, he was also a member of the executive management board of Bank of America’s Swiss legal entity.

He is a CFA charter holder and has a Master's degree from the University of St. Gallen (Switzerland).

An avid sports fan and enthusiastic skier, Alex serves on the executive board of the elite alpine ski racing division of the Zurich Ski Federation.

Prof. Dr. med. Christoph Schankin

Chief Medical Officer (CMO)

Christoph is Zynnon’s Chief Medical Officer (CMO), responsible for the company’s clinical strategy. He oversees the execution of clinical programs and liaises with the technical, scientific and medical communities.

Christoph is Professor of Neurology at the University of Bern and a consultant neurologist at Inselspital, Bern University Hospital.

For almost 20 years, he has been involved as the principal investigator in international and national clinical trials, as well as serving as an advisor for many pharmaceutical companies, and publishing more than 100 original research articles, reviews and book chapters.
After completing his medical training at the University of Heidelberg, University of York, and Columbia University, he specialised in Neurology at the University of Munich with a focus on headache, intensive care medicine, acute neurology, epilepsy, and general neurology.
During a post-doctoral fellowship at the University of California, San Francisco (UCSF), he performed extensive clinical research in human models of migraine and was the first to describe the migraine-related visual disturbance, “visual snow syndrome“.

Juliana Acosta

Office Manager & Head of Communications

Juliana is Zynnon’s Office Manager and Head of Communications.

She formerly worked as a HR consultant focusing on recruitment, training and change management. Her previous roles include a talent management position at Total in Paris (France) and, from 2011, positions at small companies in the areas of recruitment, personnel and administrative management.

Juliana graduated in psychology from the University of Paris. She also holds a Master’s degree in Human Resource Management from INSEEC-Paris.

In addition to her work at Zynnon, she is a parenting coach and provides Spanish and Culture courses for children in the canton of Schwyz (Switzerland). Juliana has lived in 5 countries and speaks 4 languages.

Prof. Dr. med. Didier Guillemot


Prof. Dr. med. Didier Guillemot is an Advisor to Zynnon.

Prof. Guillemot is a French Doctor specializing in infectious disease, and director of the Pharmacoepidemiology and Infectious Diseases research group at Institut Pasteur (https://www.pasteur.fr). He is also a researcher at Inserm (French National Institute of Health and Medical Research - https://www.inserm.fr).

From May 2016 to September 2017, he was President of Versailles Saint-Quentin-en-Yvelines University (UVSQ - https://www.uvsq.fr), where he has been teaching since 2007.

He received his PhD in technological innovation and public health from the University of Paris-Diderot (https://u-paris.fr) in 1997, going on to obtain an HDR (habilitation to conduct research) in 2003.

Prof. Guillemot was also a member of the Scientific Advisory Board of the Agence Nationale de Sécurité du Médicament et des Produits de Santé (French National Agency for the Safety of Medicines and Health Products - https://ansm.sante.fr) and of the Institut de Veille Sanitaire (French National Public Health Agency - https://www.santepubliquefrance.fr).

Dr. med. Bruno Pinna

Clinical Study Doctor

Dr. med. Bruno Pinna is a Clinical Study Doctor at Zynnon.

Dr. Pinna is a general practitioner with 7 years of clinical experience in general medicine and traumatology consultation in Paris France.

Between 2019 and 2022, he was investigator on clinical trials in cardiology, endocrinology, and onco-cardiology, at the Paris-Est Clinical Investigation Center at the Pitié Salpêtrière hospital in Paris, following which he obtained the French diploma for investigators in clinical trials (Diplôme Inter-universitaire de Formation des Investigateurs aux Essais Cliniques des médicaments (DIU-FIEC)) from Paris-Sorbonne University.

He currently works in internal medicine at the Louis Mourier Hospital in Colombes, in addition to which he remains dedicated to pursuing his interest in clinical research, focused on improving the future care of patients.

Prof. Suzanne Suggs


Prof. Suzanne Suggs is an Advisor to Zynnon.

Suzanne has over 20 years of experience in health behavior, promotion, communication, and marketing in private industry and academia.
Her work focuses on understanding behavior and acceptance of health prevention measures and then designing solutions to support people’s aim for healthier lives. She has designed, developed, and evaluated IT products and programmes to support self-management, improve prevention behaviors and patient care in many countries and settings.

Suzanne is currently a Professor of Social Marketing at the Università delle Svizzera italiana in Lugano Switzerland, Vice-President of the Swiss School of Public Health, Visiting Reader in the Institute of Global Health Innovation, Faculty of Medicine at Imperial College London, co-speaker of the expert group on Science Communication of the Swiss Academies of Arts and Sciences, and is a member of the Swiss National COVID-19 Science Task Force.

She was a Post-doctoral researcher focused on Healthy Ageing in the Evidence-based Practice Center, Department of Clinical Epidemiology and Biostatistics, at McMaster University. She earned her PhD and a Master of Science in Health Studies from Texas Woman’s University, and a Bachelor of Business Administration in Marketing from the University of North Texas. Previously she was an Assistant Professor of Health Communication at Emerson College and Adjunct Assistant Clinical Professor, Department of Public Health and Family Medicine, at Tufts University School of Medicine.

Prof. Dr. med. Elisabeth Aslangul


Prof. Dr. med. Elisabeth Aslangul is an Advisor to Zynnon.

Prof. Aslangul has over 25 years of experience in clinical research and clinical trials. She is Head of the ambulatory department and the internal medicine service of the University Hospital of Colombes APHP (Assistance Publique Hopitaux de Paris).

Since 2001 she has been teaching at the Paris Cité University.

Prof. Aslangul received her PhD in biology from the University of Paris-Diderot in 2005, moving on to obtain an HDR (habilitation to conduct research) in 2015.

She currently serves as an evaluating board member for medications on behalf of the HAS (Haute Autorité de la Santé), in addition to assuming senior roles on various committees of GHU Nord (Groupe Hôpital Universitaire Nord de l’APHP).

Zynnon has strong values.

Human welfare shapes our core values. Our primary goal is to give millions of people access to leading-edge products, enabling rapid diagnostics. This commitment not only improves the sustainability of healthcare systems but also plays a significant role in reducing healthcare costs.

High ethical standards.

Our uncompromising personal ethics underpin everything we do. Honesty, empathy and courage are key values that guide our decisions and drive our actions.

Zynnon has strong
and high ethical standards.

Our story

Khaled and Alex first met on the side of the football pitch where their respective children were playing, Together with Christoph, they bring not only decades of experience in entrepreneurship and corporate business, but add in-depth medical and clinical research experience.

In addition to its experienced management team, Zynnon surrounded himself with highly experienced medical advisors from internationally acclaimed institutions.

We aim to innovate in diagnostics beyond the laboratory, prioritizing patient-centric solutions, which relieve care personnel from continuous sampling pressures, discharge labs from unnecessary tasks, and significantly reduce time to results. Our bedside solution, in conjunction with our AI-driven cloud platform, empowers healthcare professionals to administer the appropriate antibiotic treatment and monitor its effectiveness, ensuring optimal care delivery, thus lowering healthcare cost and saving lives.

Our global strategy

Zynnon stands at the forefront of transforming respiratory infection diagnostics through groundbreaking noninvasive bedside monitoring. Our solution, powered by advanced AI and gas biomarkers detection, redefines patient care by addressing critical challenges such as Hospital-Acquired Infections (HAI) and the looming threat of Antimicrobial Resistance (AMR).

Our solution places unprecedented control in the hands of healthcare professionals. They will be able to administer precise antibiotic treatments with unparalleled accuracy, ensuring not only optimal care delivery but also real-time surveillance of treatment effectiveness.

Zynnon's commitment extends beyond individual patient care; it resonates with a profound impact on global healthcare outcomes, addressing the challenge of AMR, and strategically reducing healthcare costs. As we initially set our sights on hospitals, our vision encompasses an expansion into nursing homes and diverse home care models, including the innovative hospital at home setting. This approach empowers elderly individuals to enjoy extended, secure stays in the familiarity of their homes.

Join us in this transformative journey to shape the future of healthcare and save lives on a global scale.

Discover our solution